Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Update

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the recipient of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totaling 244,306 shares, a decrease of 18.0% from the March 31st total of 297,898 shares. Approximately 4.3% of the company’s stock are short sold. Based on an average daily volume of 55,070 shares, the short-interest ratio is currently 4.4 days.

Analyst Ratings Changes

ARMP has been the subject of a number of analyst reports. JonesTrading assumed coverage on Armata Pharmaceuticals in a report on Monday, January 5th. They issued a “buy” rating and a $15.00 price target for the company. HC Wainwright increased their target price on Armata Pharmaceuticals from $9.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, February 23rd. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Armata Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $15.00.

Institutional Trading of Armata Pharmaceuticals

Several large investors have recently added to or reduced their stakes in ARMP. Jane Street Group LLC acquired a new stake in Armata Pharmaceuticals in the 4th quarter valued at approximately $108,000. Millennium Management LLC acquired a new stake in Armata Pharmaceuticals in the 4th quarter valued at approximately $164,000. OMERS ADMINISTRATION Corp acquired a new stake in Armata Pharmaceuticals in the 4th quarter valued at approximately $177,000. SeaCrest Wealth Management LLC increased its position in Armata Pharmaceuticals by 17.3% in the 4th quarter. SeaCrest Wealth Management LLC now owns 40,988 shares of the company’s stock valued at $274,000 after acquiring an additional 6,034 shares during the period. Finally, Goldman Sachs Group Inc. acquired a new stake in Armata Pharmaceuticals in the 4th quarter valued at approximately $284,000. 3.57% of the stock is currently owned by institutional investors and hedge funds.

Armata Pharmaceuticals Price Performance

Shares of NYSEAMERICAN ARMP traded down $1.09 during mid-day trading on Friday, hitting $8.89. The company had a trading volume of 56,696 shares, compared to its average volume of 68,916. The stock has a market cap of $326.17 million, a price-to-earnings ratio of -1.84 and a beta of 1.31. Armata Pharmaceuticals has a 12 month low of $1.17 and a 12 month high of $16.34. The firm’s 50 day simple moving average is $10.72 and its two-hundred day simple moving average is $7.84.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last announced its quarterly earnings results on Wednesday, March 25th. The company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($3.23). The company had revenue of $1.09 million during the quarter, compared to analyst estimates of $0.74 million.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.